Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
144 hedge funds and large institutions have $336M invested in Intercept Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 60 reducing their positions, and 18 closing their positions.
226% more call options, than puts
Call options by funds: $28.3M | Put options by funds: $8.68M
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
3% less funds holding
Funds holding: 148 → 144 (-4)
15% less capital invested
Capital invested by funds: $397M → $336M (-$61.1M)
37% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.92M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.08M |
| 3 |
QC
Quantedge Capital
Singapore
|
+$3.95M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$3.12M |
| 5 |
Renaissance Technologies
New York
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$4.98M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.35M |
| 3 |
Millennium Management
New York
|
-$2.49M |
| 4 |
Two Sigma Advisers
New York
|
-$2.15M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.09M |
ICPT Hedge Fund Activity: Q2 2022 in Review
144 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2022, worth a combined $336M — down 15% from $397M a quarter earlier.
Fund positioning in ICPT was balanced in Q2 2022: 18 funds opened new positions, 18 closed out, 38 added to existing stakes and 60 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $7.92M. The largest seller was Two Sigma Investments, cutting an estimated $4.98M.
- 144 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2022, down from 148 in Q1 2022.
- Funds reported $336M of Intercept Pharmaceuticals, Inc. stock for Q2 2022, down 15% quarter-over-quarter.
- 18 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2022 and 18 closed out, a net change of 0 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2022 was Morgan Stanley, an estimated $7.92M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2022 was Two Sigma Investments, an estimated $4.98M sold.
Based on aggregated 13F filings for Q2 2022.